|
|
Post by joeypotsandpans on Jan 6, 2016 8:50:43 GMT -5
At what reasonable price point do you think the insurance cos. would have to instantly move to Tier 2 without hesitation? Novo did it with Levemir and Novolog to gain essentially "monopolistic" contracts with certain providers, MNKD should now use their same tactics with the superior product (save the label comments) and beat them at their own game... It's all about the $$$ to the insurance whores. I would think it's time for the scorned Mann's gloves to come off and make it not feasible for the insurance cos. to keep Afrezza off Tier 2 status anymore. Time to take this battle to the bottom line and set the price war in motion...let's see how fast that gets a resolution to this BP game that's been played. They tried the conventional approach via an inept SNY, time to go non traditional and create the push that's been waiting. Create the flood to break the gates open and get those 3 lines cranking. Better product, lower price = instant created demand and ultimate success. Yes it can be that easy if you have the better product and the wherewithal to set a price they can't refuse. Next week's conference is an opportunity to come out swinging, Matt alluded in the call yesterday that pricing is an option, I liked his last statement... "We view this as an opportunity NOT an obstacle" ....in the end Brandicourt and his so called bs dtc magazine strategy will go by the way of Napoleon and show him as the idiot he truly is for letting this holy grail that he had in his grasp get away IMO. It's a new day carpe diem  |
|
|
|
Post by silentknight on Jan 6, 2016 8:55:24 GMT -5
I'd find the price of Toujeo or Lantus, match it, and cut it by 15%.
Create demand first, get good results, create patient loyalty and then look to raise prices later, GRADUALLY.
100% of 50 is still better than 35% of 100. That's what I would do if I were MNKD.
|
|
|
|
Post by joeypotsandpans on Jan 6, 2016 9:02:47 GMT -5
I'd find the price of Toujeo or Lantus, match it, and cut it by 15%. Create demand first, get good results, create patient loyalty and then look to raise prices later, GRADUALLY. 100% of 50 is still better than 35% of 100. That's what I would do if I were MNKD. It's not "directly" competing with those as they're not prandial, but haircutting 20% under current Novolog, Humalog should be a nice wake up call to providers, competitors, physicians, and patients. Time to stir up the hornets nest. |
|
|
|
Post by silentknight on Jan 6, 2016 9:07:55 GMT -5
I'd find the price of Toujeo or Lantus, match it, and cut it by 15%. Create demand first, get good results, create patient loyalty and then look to raise prices later, GRADUALLY. 100% of 50 is still better than 35% of 100. That's what I would do if I were MNKD. It's not "directly" competing with those as they're not prandial, but haircutting 20% under current Novolog, Humalog should be a nice wake up call to providers, competitors, physicians, and patients. Time to stir up the hornets nest. True, but it'd do it to prove a point to Sanofi. Either way, the price needs to come WAY down and you'd see insurance coverage change soonest. |
|
|
|
Post by peppy on Jan 6, 2016 9:16:49 GMT -5
I think 4 dollars a day Afrezza could be given try.
I think Canada and the European union National Health Care would cover at that price.
A vial of injectable fast acting, we once looked at to be $3.19 a day all doses. Apidra.
(by memory, the thread somewhere.)
|
|
|
|
Post by mnholdem on Jan 6, 2016 9:18:58 GMT -5
MnHoldem's Support Plan for U.S. Commercialization of Afrezza:
1. Lower the price to below current RAA insulin (Novolog, Humulog);
2. Prove superiority via FDA-approved postmarket trial ASAP; 2a. Fund university studies to confirm previous studies demonstrating 40% effectiveness of early insulin treatment for remission of disease;
3. Raise price of Afrezza based on superiority data.
#1 may lead to better Tier coverage
#2 definitely will lead to better Tier coverage
#3 by then, market penetration and demand for Afrezza will prevail... just don't raise the price too much! |
|
|
|
Post by suebeeee1 on Jan 6, 2016 9:19:27 GMT -5
I think 4 dollars a day Afrezza could be given try. I think Canada and the European union National Health Care would cover at that price. A vial of injectable fast acting, we once looked at to be $3.19 a day all doses. Apidra. (by memory, the thread somewhere. In order to get approved in the EU, there is a process that takes (at least) months. Afrezza needs to go through their equivalent of the FDA. Regardless, all the studies have been done to get FDA approval, but the applications must be undertaken. I do hope someone has had that paperwork ready to be submitted in anticipation of SNYs move. |
|
|
|
Post by hawaiiguy42 on Jan 6, 2016 9:22:55 GMT -5
I'd find the price of Toujeo or Lantus, match it, and cut it by 15%. Create demand first, get good results, create patient loyalty and then look to raise prices later, GRADUALLY. 100% of 50 is still better than 35% of 100. That's what I would do if I were MNKD. l, but haircutting 20% under current Novolog, Humalog should be a nice wake up call to providers, competitors, physicians, and patients. Time to stir up the hornets nest. But doesn't it undercut prandial's and/or basil's by having to use less? |
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Jan 6, 2016 9:23:39 GMT -5
i would start with payers in CA and FL
|
|
|
|
Post by mnholdem on Jan 6, 2016 9:24:56 GMT -5
hawaiiguy42 ,
Payers group Tiers by treatment type. They wouldn't rate a slow-action basal against a rapid-acting insulin. |
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Jan 6, 2016 9:29:14 GMT -5
can MNKD do this in the next few weeks if it can move fast or wait until April 6th - the official termination date with yesterday being the notice date?
|
|
|
|
Post by hawaiiguy42 on Jan 6, 2016 9:30:58 GMT -5
Got it, thanks.
|
|
|
|
Post by joeypotsandpans on Jan 6, 2016 9:31:28 GMT -5
It's not "directly" competing with those as they're not prandial, but haircutting 20% under current Novolog, Humalog should be a nice wake up call to providers, competitors, physicians, and patients. Time to stir up the hornets nest. But doesn't it undercut prandial's and/or basil's by having to use less? That's why I put the quotes around directly as those are claims being made by some current T1 users but still would need to be substantiated medically via trials I would imagine. In due time my friend |
|
|
|
Post by greg on Jan 6, 2016 9:32:59 GMT -5
I'd find the price of Toujeo or Lantus, match it, and cut it by 15%. Create demand first, get good results, create patient loyalty and then look to raise prices later, GRADUALLY. 100% of 50 is still better than 35% of 100. That's what I would do if I were MNKD. It's not "directly" competing with those as they're not prandial, but haircutting 20% under current Novolog, Humalog should be a nice wake up call to providers, competitors, physicians, and patients. Time to stir up the hornets nest. Have to be careful cutting price. Price obviously needs to be lowered but keep in mind NVO and LLY have far far greater fire power and a price war among three players doesn't make sense for MNKD. |
|
|
|
Post by matt on Jan 6, 2016 9:36:10 GMT -5
haircutting 20% under current Novolog, Humalog should be a nice wake up call. Can MNKD produce, market, and sell the product profitably with a 20% price cut? Does anybody know the all-inclusive cost of sales per unit versus was a 20% discount to managed care pricing would look like? Afrezza is not as efficient as injected insulin due to the amount of drug not absorbed via the lung, so there is more active pharmaceutical ingredient required to deliver an equivalent therapeutic dose, plus the additional cost of the device and delivery system. What are the real economics of that "wake up call"? |
|
